These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29551624)

  • 1. Assessment of Tdap Vaccination Effectiveness in Adolescents in Integrated Health-Care Systems.
    Briere EC; Pondo T; Schmidt M; Skoff T; Shang N; Naleway A; Martin S; Jackson ML
    J Adolesc Health; 2018 Jun; 62(6):661-666. PubMed ID: 29551624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.
    Acosta AM; DeBolt C; Tasslimi A; Lewis M; Stewart LK; Misegades LK; Messonnier NE; Clark TA; Martin SW; Patel M
    Pediatrics; 2015 Jun; 135(6):981-9. PubMed ID: 25941309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waning Tdap Effectiveness in Adolescents.
    Klein NP; Bartlett J; Fireman B; Baxter R
    Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine.
    Terranella A; Rea V; Griffith M; Manning S; Sears S; Farmer A; Martin S; Patel M
    Vaccine; 2016 May; 34(22):2496-500. PubMed ID: 27038131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.
    Koepke R; Eickhoff JC; Ayele RA; Petit AB; Schauer SL; Hopfensperger DJ; Conway JH; Davis JP
    J Infect Dis; 2014 Sep; 210(6):942-53. PubMed ID: 24903664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis.
    Breakwell L; Kelso P; Finley C; Schoenfeld S; Goode B; Misegades LK; Martin SW; Acosta AM
    Pediatrics; 2016 May; 137(5):. PubMed ID: 27244813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis.
    Skoff TH; Martin SW
    JAMA Pediatr; 2016 May; 170(5):453-8. PubMed ID: 27018748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
    Havers FP; Cho BH; Walker JW; Hariri S
    Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.
    Cho BH; Acosta AM; Leidner AJ; Faulkner AE; Zhou F
    Prev Med; 2020 May; 134():106066. PubMed ID: 32199910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
    Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
    MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(1):13-5. PubMed ID: 21228763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal Conjugate and Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccination Among HIV-infected Youth.
    Setse RW; Siberry GK; Moss WJ; Wheeling J; Bohannon BA; Dominguez KL;
    Pediatr Infect Dis J; 2016 May; 35(5):e152-7. PubMed ID: 26855409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
    MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation.
    Skoff TH; Blain AE; Watt J; Scherzinger K; McMahon M; Zansky SM; Kudish K; Cieslak PR; Lewis M; Shang N; Martin SW
    Clin Infect Dis; 2017 Nov; 65(12):1977-1983. PubMed ID: 29028938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.